CAFC Reverses Massive Jury Verdict for Juno and Sloan Kettering
IP Watchdog
AUGUST 26, 2021
The patent generally covers cancer immunotherapy technology. The jury ultimately found in Juno’s favor and, in post-trial briefs, Kite moved for judgment as a matter of law (JMOL) on several grounds, including that the claims were not supported by sufficient written description. Juno sued Kite Pharma, Inc.
122 
Let's personalize your content